Downregulation of HBx mRNA in HepG2.2.15 cells by small interfering RNA

被引:6
作者
Jiao, Jing [1 ]
Cao, Hong [2 ]
Chen, Xiao-Wei [1 ]
Zhou, Mei-juan [1 ]
Liu, Zhi-hua [3 ]
Ding, Zhen-hua [1 ]
机构
[1] So Med Univ, Sch Publ Hlth & Trop Med, Dept Radiat Med, Guangzhou 510515, Guangdong, Peoples R China
[2] So Med Univ, Dept Microbiol, Guangzhou 510515, Guangdong, Peoples R China
[3] Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China
关键词
hepatitis B virus x protein; HepG2.2.15; cells; real-time reverse-transcript PCR; RNA interference; small interfering RNA; western blot;
D O I
10.1097/MEG.0b013e3282748ee2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective Hepatitis B virus (HBV) infection is one of the most prevalent viral infectious diseases in humans. And it is still a challenge for the development of an effective therapy for HBV infection. Recently, the progress in RNA interference (RNAi) has shed some light on the inhibition of HBV expression and replication by RNAi specific for the various genes of the HBV genome. Some prior researches suggests that the HBV x protein (HBx) plays an important role in viral transcription, cell growth, and apoptotic cell death. Methods In the present study, we designed three siRNAs based on the X-protein of HBV sequences and tested their effects on the expression of HBx gene following sorting of siRNA-positive cells. The interference effect was tested in 24, 48, and 72 h. HBsAg in cultured media was assayed using western blot at various days post-transfection. The amount of HBx mRNA was quantitated by Real-time reverse-transcript PCR (RT-PCR). Results There was a decrease in the levels of HBV mRNA and HBsAg from the the transfected cells. Among these three siRNAs, siRNA-2 was found to be the most effective at suppressing HBV gene expression.
引用
收藏
页码:1114 / 1118
页数:5
相关论文
共 32 条
[1]  
Andrisani OM, 1999, INT J ONCOL, V15, P373
[2]  
[Anonymous], FIELDS VIROLOGY
[3]   A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B [J].
Chang, TT ;
Gish, RG ;
de Man, R ;
Gadano, A ;
Sollano, J ;
Chao, YC ;
Lok, AS ;
Han, KH ;
Goodman, Z ;
Zhu, J ;
Cross, A ;
DeHertogh, D ;
Wilber, R ;
Colonno, R ;
Apelian, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1001-1010
[4]  
Chisari FV, 1996, CURR TOP MICROBIOL, V206, P149
[5]   RNA interference: antiviral defense and genetic tool [J].
Cullen, BR .
NATURE IMMUNOLOGY, 2002, 3 (07) :597-599
[6]   Anti-HBV effect of TAT- HBV targeted ribonuclease [J].
Ding, J ;
Liu, J ;
Xue, CF ;
Gong, WD ;
Li, YH ;
Zhao, Y .
WORLD JOURNAL OF GASTROENTEROLOGY, 2003, 9 (07) :1525-1528
[7]   Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection [J].
Doo, E ;
Liang, TJ .
GASTROENTEROLOGY, 2001, 120 (04) :1000-1008
[8]   Virologic response and resistance to adefovir in patients with chronic hepatitis B [J].
Fung, SK ;
Chae, HB ;
Fontana, RJ ;
Conjeevaram, H ;
Marrero, J ;
Oberhelman, K ;
Hussain, M ;
Lok, ASF .
JOURNAL OF HEPATOLOGY, 2006, 44 (02) :283-290
[9]  
Ghany MG, 2000, HEPATOLOGY, V32, p376A, DOI 10.1053/jhep.2000.17912
[10]   Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B [J].
Hadziyannis, SJ ;
Tassopoulos, NC ;
Heathcote, EJ ;
Chang, TT ;
Kitis, G ;
Rizzetto, M ;
Marcellin, P ;
Lim, SG ;
Goodman, Z ;
Ma, J ;
Arterburn, S ;
Xiong, S ;
Currie, G ;
Brosgart, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (26) :2673-2681